Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
29 January 2024 | Story Leonie Bolleurs | Photo Supplied
Zola Valashiya
Nearly a decade ago, Zola Valashiya completed his LLB at UFS and is currently working towards his second LLM in Technology and Innovation at the Seattle University School of Law.

Zola Valashiya graduated from the UFS almost ten years ago with an LLB. Since then, amid life’s twists and turns, he obtained an LLM from the University of Washington, secured a job with a successful law firm in the US, and married the love of his life. Currently, Zola is pursuing a second LLM in Technology and Innovation with the Seattle University School of Law.

Following the advice of a dear friend, Zola figured out what drives him and pursued it relentlessly. “This very simple piece of advice taught me the value of my time, and how much power you take back when you prioritise and protect it,” he remarks.

Advancing the greater good

Fast forward nine-plus years since UFS graduation day, Zola works as a strategic adviser at Coopersmith Law + Strategy, a boutique firm in Seattle specialising in health care, global health, gender/racial equality, and climate health.

“The legal work I do involves various tasks, from drafting legal contracts to conducting data analysis, and developing business strategies for deploying new technologies in health systems or addressing climate change. I value this environment because our efforts are focused on advancing the greater good. I have the opportunity to work on projects that I know will benefit individuals, communities, and the planet,” says Zola.

One of the highlights of his career occurred during the pandemic when he played a key role in preserving one of the largest US training programmes for physicians from diverse backgrounds who serve marginalised communities.

He explains, “The pandemic placed a strain on health-care systems worldwide, leading to cost-cutting measures in private hospitals, the termination of community health programmes, and the closure of small clinics in remote areas, in order to recover from the financial losses. However, these programmes and clinics are vital to the communities they serve because the nurses and doctors are often the only health-care providers for miles around. My contributions have helped to ensure the programme’s continuation, and the continued delivery of quality health care to underserved communities.”

Diversifying his skill set

For the future, Zola says he is working towards diversifying his skill set. “The modern-day lawyer needs to know more than just the law. I have learned coding skills, and I am currently focused on expanding my knowledge of artificial intelligence. In so doing, I am equipping myself with the necessary tools and expertise to thrive in this rapidly evolving field, thereby future-proofing my career.

News Archive

National Department of Health invests R53.5 million in UFS laboratory
2016-02-04

Description: Dr Derek Litthauer Tags: Dr Derek Litthauer

Dr Derek Litthauer
Photo: Supplied

This year has started off on a high note for Dr Derek Litthauer and his team at the South African National Control Laboratory (NCL) for Biological Products. The National Department of Health has awarded the NCL a contract to the value of R53.5 million to continue testing vaccines for the next three years.

Vaccines are biological medicines used to ensure healthy populations by preventing many diseases. The World Health Organization (WHO) estimates that, worldwide, about 5.2 million children under six years old die annually. Of these deaths, 29% are vaccine preventable. Research has revealed that vaccines prevent about 6 million deaths each year globally. Safe and effective vaccines are essential public health tools, which are strictly regulated internationally. It is the NCL’s responsibility to perform quality control testing on all vaccines to be used on humans in South Africa.

This laboratory, the only one of its kind in Africa, receives samples of vaccines from manufacturers and importers for rigorous evaluation and testing. No vaccine may be used in South Africa without a release certificate issued by the Control Lab, certifying that the vaccine is suitable for human use.

The contract is a commitment to ensuring that only vaccines of the highest quality are used in South Africa.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept